Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1666 to 1680 of 7682 results

  1. Dabigatran etexilate for the secondary prevention of stroke after an embolic stroke of undetermined source (ID1417)

    Awaiting development [GID-TA10426] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Tinnitus

    Awaiting development [GID-QS10091] Expected publication date: TBC

    Quality standard
    Awaiting development

  3. Cositecan for treating platinum or taxane resistant advanced, mucinous, epithelial ovarian cancer [ID826]

    In development [GID-TA10446] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Heart valve disease in adults

    Awaiting development [GID-QS10101] Expected publication date: TBC

    Quality standard
    Awaiting development

  5. Diverticular disease

    Awaiting development [GID-QS10086] Expected publication date: TBC

    Quality standard
    Awaiting development

  6. Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women ID1401

    In development [GID-TA10326] Expected publication date: TBC

    Technology appraisal guidance
    In development

  7. Infant, children and young people's experience of health care

    Awaiting development [GID-QS10102] Expected publication date: TBC

    Quality standard
    Awaiting development

  8. Ibrutinib for treating relapsed or refractory follicular lymphoma [1251]

    In development [GID-TA10223] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Veliparib with carboplatin and paclitaxel for untreated non-squamous non-small-cell lung cancer [ID1277]

    In development [GID-TA10248] Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Shared decision-making: practical guidance for health and social care professionals

    Awaiting development [GID-QS10097] Expected publication date: TBC

    Quality standard
    Awaiting development

  11. Vocimagene amiretrorepvec with extended-release 5-fluorocytosine for treating recurrent high-grade glioma [ID1425]

    In development [GID-TA10542] Expected publication date: TBC

    Technology appraisal guidance
    In development

  12. Gosuranemab for treating progressive supranuclear palsy [ID1607]

    Awaiting development [GID-TA10553] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Cediranib with olaparib for treating recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer after 3 therapies [ID1639]

    In development [GID-TA10607] Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. MTX110 for untreated diffuse intrinsic pontine glioma [ID2695]

    In development [GID-TA10573] Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Atezolizumab for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730]

    In development [GID-TA10623] Expected publication date: TBC

    Technology appraisal guidance
    In development